Nucpaedia
Nucpaedia
0%
Radionuclide therapy

¹⁷⁷Lu-DOTATATE

Source: NANETS/SNMMI 2019 · confirm locally
0 / 19
Educational aid — verify against EANM/SNMMI/ATA/NCCN, the drug label and local protocol. Session-only.
1

Before planning therapy

2

During therapy — each cycle

3

After each cycle & follow-up

Background & evidence

¹⁷⁷Lu-DOTATATE (lutetium oxodotreotide, Lutathera) is a somatostatin analogue labelled with the β⁻ emitter ¹⁷⁷Lu. It binds somatostatin receptors, with highest affinity for subtype 2, is internalised, and irradiates tumour cells and their neighbours (mean tissue range 0.67 mm, maximum 2.2 mm). It is the standard next step after progression on a somatostatin analogue in SSTR-positive gastroenteropancreatic NETs (NETTER-1; ASCO 2023). NETTER-2 supports first-line use in higher-grade G2–G3 disease.

Indications & contraindications

Indications

  • US label (revised 10/2024): adults and children aged 12 years or older with SSTR-positive GEP-NETs, including foregut, midgut and hindgut tumours. The label wording sets no grade limit.
  • EU SmPC: adults with unresectable or metastatic, progressive, well-differentiated G1–G2 SSTR-positive GEP-NETs. G3 tumours and adolescents are outside the EU licence.
  • SSTR imaging (PET or scintigraphy) must show tumour uptake at least as high as normal liver (EU SmPC). NETTER-1 required receptor expression on all lesions (OctreoScan uptake ≥ normal liver) and Ki-67 ≤20%.
  • ASCO 2023: after progression on a somatostatin analogue, PRRT is recommended for SSTR-positive GI-NETs and is a second-line option for SSTR-positive pancreatic NETs.
  • First line in G2–G3 disease: newly diagnosed advanced GEP-NETs with Ki-67 ≥10% to ≤55% and SSTR uptake in all target lesions (NETTER-2). Within the US label wording; outside the EU G1–G2 licence. Decide at the MDT.
  • Retreatment after an earlier response is a tumour-board decision that must account for previous kidney and marrow doses (IAEA/EANM/SNMMI 2013).

Contraindications

  • Pregnancy (established, suspected or not excluded): contraindicated in the EU SmPC. The US label lists no contraindications but warns of fetal harm.
  • Creatinine clearance <30 mL/min: contraindicated in the EU SmPC. In the US label, severe impairment has not been studied, and mild–moderate impairment (30–89 mL/min) needs closer renal monitoring. NETTER-1 required clearance ≥50 mL/min.
  • Grade 3–4 hypersensitivity to a previous dose: do not rechallenge (US label).
  • Relative: tumour uptake below liver or dominant SSTR-negative disease; poor marrow reserve (prior myelotoxic chemotherapy or wide-field radiotherapy to pelvis or spine raises the risk of marrow failure; NETTER-1 excluded radiotherapy to >25% of marrow); severe hepatic impairment (bilirubin >3 × ULN, not studied).
  • Breastfeeding must stop (see radiation protection).
Activity, dosing & administration
ItemRecommendationSource
Activity and schedule7.4 GBq (200 mCi) every 8 weeks (±1 week) for 4 doses; cumulative 29.6 GBq. Same activity for children aged ≥12 years.US label; EU SmPC
Amino acids (US)L-lysine HCl 18–25 g + L-arginine HCl 18–25 g in 1–2 L, osmolality <1200 mOsmol/kg. Start 30 min before; continue during and for ≥3 h after.US label
Amino acids (EU)L-lysine HCl 25 g + L-arginine HCl 25 g in 1 L, over 4 h, starting 30 min before. Separate arm preferred. Lysine–arginine-only solutions preferred (lower volume and osmolality).EU SmPC
Amino-acid doseNever reduce it, even when the Lutathera dose is reduced.US label; EU SmPC
AntiemeticGive before the amino-acid infusion.US label
OctreotideStop long-acting analogue ≥4 weeks and short-acting ≥24 h before each dose. Octreotide LAR 30 mg IM 4–24 h after each dose. After the course, 30 mg every 4 weeks until progression or 18 months from the start.US label
Reduced dose3.7 GBq (100 mCi) after a qualifying toxicity resolves; return to 7.4 GBq for the next dose if the reduced dose is tolerated.US label; EU SmPC
Permanent stopThe same toxicity recurs, a toxicity needs the interval extended beyond 16 weeks, or grade 3–4 hypersensitivity occurs.US label; EU SmPC
  • Haematological holds: thrombocytopenia grade ≥2 (platelets <75 ×10⁹/L): withhold until grade 0–1. Anaemia grade ≥3 (Hb <8.0 g/dL) or neutropenia grade ≥3 (ANC <1.0 ×10⁹/L): withhold until grade 0–2. Then resume at 3.7 GBq. Lymphopenia alone needs no change (US label; CTCAE thresholds from the EU SmPC).
  • Renal holds: creatinine clearance <40 mL/min (Cockcroft–Gault, actual weight), a 40% rise in serum creatinine, or a 40% fall in clearance from baseline. Withhold until resolution or return to baseline, then resume at 3.7 GBq.
  • Hepatic holds: bilirubin >3 × ULN, or albumin <30 g/L with INR >1.5. Other non-haematological grade 3–4 toxicity: withhold until grade 0–2.
  • Typical organ doses: in NETTER-1 (n=20), 4 × 7.4 GBq gave mean absorbed doses of 19.4 ± 8.7 Gy to the kidneys (0.654 Gy/GBq) and 1.0 ± 0.8 Gy to red marrow (0.035 Gy/GBq). The spleen received 25.1 Gy (US label).
  • Dosimetry-based protocols (practice-dependent, not in the label): further 7.4 GBq cycles are given until an organ limit is reached. Uppsala: kidney absorbed dose 23 Gy, red marrow 2 Gy. Lund: renal BED 27 ± 2 Gy (α/β 2.6 Gy), extended to 40 ± 2 Gy in selected patients. Earlier renal BED thresholds of 28 Gy with risk factors (hypertension, diabetes) and 40 Gy without came mainly from ⁹⁰Y-DOTATOC data. Follow your own centre protocol.
  • Observe for at least 2 h after infusion where resuscitation drugs and equipment are available. Premedicate after a previous grade 1–2 hypersensitivity reaction (US label).
Key trials & evidence
Trial / studyPopulationResultReference
NETTER-1 (phase 3)229 patients with progressive, well-differentiated, SSTR-positive midgut NET on octreotide LAR. ¹⁷⁷Lu-DOTATATE 7.4 GBq × 4 + octreotide LAR 30 mg vs octreotide LAR 60 mg every 4 weeks.PFS at 20 months 65.2% vs 10.8%. Median PFS not reached vs 8.5 months, HR 0.21 (US label). Response 18% vs 3%. Grade 3–4 neutropenia 1%, thrombocytopenia 2%, lymphopenia 9%.Strosberg 2017
NETTER-1 final OS231 randomised; median follow-up 76 months.Median OS 48.0 vs 36.3 months, HR 0.84, p=0.30 (not significant). MDS in 2 of 111 (2%). No new MDS or AML during long-term follow-up.Strosberg 2021
NETTER-2 (phase 3)226 patients aged ≥15 years with newly diagnosed advanced G2 (Ki-67 10–20%) or G3 (Ki-67 >20–55%) SSTR-positive GEP-NET. 2:1 to ¹⁷⁷Lu-DOTATATE × 4 + octreotide LAR 30 mg vs octreotide LAR 60 mg.Median PFS 22.8 vs 8.5 months, stratified HR 0.276. No study drug-related deaths during treatment.Singh 2024
ERASMUS (label safety cohort)Single-centre expanded access; 1214 patients with SSTR-positive tumours.MDS 2.0% (16) and acute leukaemia 0.5% (4); median onset 29 and 55 months. Renal failure <1%, 3–36 months after treatment. Hormonal crisis <1%.US label
Uppsala dosimetry-guided cohort200 patients; 7.4 GBq cycles repeated until kidney dose reached 23 Gy.61.5% reached 23 Gy (3–9 cycles); none reached 2 Gy to marrow. Median PFS 33 vs 15 months if 23 Gy was or was not reached. Acute leukaemia 1.5%.Garske-Román 2018
Lund phase 2 (renal BED-guided)96 evaluable patients, Ki-67 <20%; 7.4 GBq every 10 ± 2 weeks up to a renal dose limit.Median 5 cycles (1–9). Partial response 16%. Median PFS 29 months, OS 47 months. Grade 3–4 toxicity <10%, none renal.Sundlöv 2022
Rotterdam late haematological toxicity274 GEP-NET patients after ¹⁷⁷Lu-DOTATATE.Persistent haematological dysfunction 4%: haematopoietic neoplasm 2.9%, marrow failure 1.1%. Median latency 41 months. No predictor found, including marrow dose.Bergsma 2018
Systematic review of t-MN28 studies; 7334 NET patients after PRRT.Mean therapy-related myeloid neoplasm incidence 2.61%; complex cytogenetics common.Sonbol 2020
Toxicity & its management
  • Myelosuppression (NETTER-1, all grades / grade 3–4): anaemia 81% / 0, thrombocytopenia 53% / 1%, neutropenia 26% / 3%. The platelet nadir falls a median of 5.1 months after the first dose; median recovery takes 2 months (US label).
  • MDS and acute leukaemia are the main late risks: MDS 2.3% in NETTER-1 at 76 months; MDS 2.0% and acute leukaemia 0.5% in ERASMUS (US label). Persistent haematological dysfunction reached 4% in a Rotterdam cohort, and 7 of its 11 cases had anaemia with a rising MCV. Refer persistent unexplained cytopenia to haematology.
  • Renal: renal failure in <1% of ERASMUS patients, 3–36 months after treatment; two of eight had prior impairment or risk factors (diabetes, hypertension) and needed dialysis (US label). Amino-acid protection is mandatory.
  • Nausea and vomiting are among the most frequent grade 3–4 reactions, alongside lymphopenia, raised GGT and transaminases, hyperglycaemia and hypokalaemia (US label). Give antiemetics before the amino acids.
  • Neuroendocrine hormonal crisis (flushing, diarrhoea, bronchospasm, hypotension) in <1%, usually during or within 24 h of the first dose. Treat with IV somatostatin analogue, fluids, corticosteroids and electrolyte correction (US label).
  • Hepatotoxicity: tumour haemorrhage, oedema or necrosis in <1% (ERASMUS); higher risk with liver metastases. Monitor transaminases, bilirubin, albumin and INR (US label).
  • Hypersensitivity, including angioedema, has occurred (US label).
  • Infertility: 29.6 GBq gives gonadal doses in the range where temporary or permanent infertility occurs after external beam radiotherapy (US label). Discuss before the first cycle.
Radiation protection & discharge
  • Follow local release rules. Example: US NRC rules (10 CFR 35.75) allow release when the dose to any other person is unlikely to exceed 5 mSv, with written instructions if it may exceed 1 mSv.
  • Activity is excreted in urine and can be detected for up to 30 days (US label). Advise hydration and frequent voiding before, on the day of and the day after treatment. Handle material soiled with urine carefully; dispose of urine and faeces under national rules (EU SmPC).
  • Typical advice after each dose (EU SmPC, alongside local rules): limit close contact (<1 m) with others for 7 days; with children or pregnant women, keep close contact under 15 minutes a day for 7 days; sleep in a separate bedroom for 7 days, and apart from children or pregnant women for 15 days.
  • Pregnancy: confirm status before treatment. Women should use effective contraception for 7 months after the last dose; men with female partners of reproductive potential for 4 months (US label; EU SmPC).
  • Breastfeeding: stop; do not breastfeed for 2.5 months after the last dose (US label).
  • Children aged ≥12 years: radiation risks are greater than in adults because of longer life expectancy; continued follow-up for late effects is recommended (US label).
  • Waste: ¹⁷⁷Lu for Lutathera may be made from ¹⁷⁶Lu or ¹⁷⁶Yb, which changes waste management. Check the batch documentation (US label).

References

  1. Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41(32):5049-67.
  2. Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE. J Nucl Med. 2019;60(7):937-43.
  3. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-16.
  4. Novartis Pharmaceuticals Corporation. Lutathera (lutetium Lu 177 dotatate) injection: US prescribing information, revised 10/2024. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55
  5. European Medicines Agency. Lutathera: summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera
  6. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-35.
  7. Strosberg JR, Caplin ME, Kunz PL, et al. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752-63.
  8. Singh S, Halperin D, Myrehaug S, et al. [¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807-17.
  9. Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970-88.
  10. Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480-9.
  11. Sundlöv A, Gleisner KS, Tennvall J, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based ¹⁷⁷Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830-40.
  12. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847-56.
  13. Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59(3):452-8.
  14. Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6(7):1086-92.
  15. US Nuclear Regulatory Commission. 10 CFR 35.75: release of individuals containing unsealed byproduct material or implants containing byproduct material. Available from: https://www.law.cornell.edu/cfr/text/10/35.75
Other therapies:
← All therapiesTheranostics